Prothena Ongoing Program Activities Sample Clauses
The "Prothena Ongoing Program Activities" clause defines the ongoing research, development, or operational tasks that Prothena is responsible for under the agreement. This clause typically outlines the specific activities, milestones, or deliverables that Prothena must continue to perform, such as conducting clinical trials, maintaining regulatory filings, or advancing a particular drug candidate. Its core function is to ensure that Prothena remains actively engaged in its obligations, providing clarity and accountability for the continuation of key program activities throughout the term of the agreement.
Prothena Ongoing Program Activities. Notwithstanding the provisions of Section 2.1.1 or Section 2.2.1, Prothena shall have the right to continue to conduct Development activities (and related activities, including as set forth in Section 2.5.1(b)(iv) of the Master Collaboration Agreement with respect to the Licensed Program) for the Licensed Program under, and in accordance with, the Master Collaboration Agreement, through the first to occur of (i) the end of the Phase 1 Option Term for the Licensed Program, or (ii) Celgene’s exercise of the ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇ Portion Participation Right; provided, however, that if thereafter, in the event that Prothena desires to conduct any Development activities (or related activities) in the Territory that are not set forth in the Master Collaboration Agreement or this Agreement, Prothena may only conduct such activities to the extent requested by Celgene in writing, or otherwise with the prior written consent of Celgene.
Prothena Ongoing Program Activities. Prothena’s obligations as set forth in this Section 2.1.3, as applicable, are the “Prothena Ongoing Program Activities”.